Using nanoparticle-coated macrophages to target breast cancer spread to the brain
Nanoparticle-coated macrophages for targeted disruption of YAP/TEAD interactions in breast cancer brain metastasis
This study is exploring a new way to help people with breast cancer that has spread to the brain by using tiny particles to help immune cells fight the cancer more effectively, and it may lead to new treatment options for patients.
Quick facts
| Grant type | R21 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of Illinois at Chicago NIH-funded |
| Lab location | 1 site (Chicago, UNITED STATES) |
| Project ID | NIH-10939097 on NIH RePORTER |
What this research studies
This research investigates a novel approach to combat brain metastasis in breast cancer by utilizing nanoparticle-coated macrophages. These specialized immune cells are designed to disrupt the interactions between YAP and TEAD proteins, which are crucial for the growth and survival of cancer cells in the brain. By targeting these interactions, the study aims to inhibit the proliferation of cancer cells that have spread to the brain, potentially leading to new treatment options. Patients may be involved in trials that assess the safety and effectiveness of this innovative therapy.
Who could benefit from this research
Good fit: Ideal candidates for this research are patients diagnosed with metastatic breast cancer who have developed brain metastases.
Not a fit: Patients with early-stage breast cancer or those without brain metastases may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to new therapies that significantly improve outcomes for patients with breast cancer that has metastasized to the brain.
How similar studies have performed: While targeting YAP-TEAD interactions is a novel approach, previous studies have shown promise in using similar strategies to inhibit cancer cell growth.
Where this research is happening
Chicago, UNITED STATES
- University of Illinois at Chicago — Chicago, United States (Active)
Researchers
- Principal investigator: Zhao, Zongmin — University of Illinois at Chicago
- Study coordinator: Zhao, Zongmin
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.